- Home
- AMC vs VRDN Comparison
AMC vs VRDN Comparison
Compare AMC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMC | VRDN |
|---|---|---|
| Founded | 1920 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMC | VRDN |
|---|---|---|
| Price | $2.90 | $22.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $3.20 | ★ $36.75 |
| AVG Volume (30 Days) | ★ 21.2M | 1.9M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | $5,706,000.00 |
| Revenue This Year | $15.83 | N/A |
| Revenue Next Year | $3.49 | $857.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $13.18 |
| 52 Week High | $3.40 | $34.29 |
Technical Indicators
Market Signals| Indicator | AMC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 62.22 |
| Support Level | $2.34 | $21.40 |
| Resistance Level | $2.93 | $23.40 |
| Average True Range (ATR) | 0.17 | 0.98 |
| MACD | -0.02 | 0.59 |
| Stochastic Oscillator | 26.67 | 81.83 |
Price Performance
Historical ComparisonAbout AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.